{"id":639641,"date":"2023-02-22T15:38:02","date_gmt":"2023-02-22T15:38:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=639641"},"modified":"2023-02-22T15:38:02","modified_gmt":"2023-02-22T15:38:02","slug":"alkpositive-nonsmall-cell-lung-cancer-pipeline-analysis-demonstrates-novel-30-therapies-at-the-horizon-expected-to-transform-the-treatment-paradigm-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alkpositive-nonsmall-cell-lung-cancer-pipeline-analysis-demonstrates-novel-30-therapies-at-the-horizon-expected-to-transform-the-treatment-paradigm-delveinsight_639641.html","title":{"rendered":"ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 30+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1677049347.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 30+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1677049347.png\" alt=\"ALK-positive Non-Small Cell Lung Cancer Pipeline Analysis Demonstrates Novel 30+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;ALK-positive Non-Small Cell Lung Cancer Pipeline Insights, 2023,&rdquo; report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including ALK-positive Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">For ALK-positive Non-Small Cell Lung Cancer emerging drugs, the ALK-positive Non-Small Cell Lung Cancer pipeline analysis report provides a 360&deg; view of the ALK-positive Non-Small Cell Lung Cancer pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The ALK-positive Non-Small Cell Lung Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the ALK-positive Non-Small Cell Lung Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, ALK-positive Non-Small Cell Lung Cancer clinical trials studies, ALK-positive Non-Small Cell Lung Cancer NDA approvals (if any), and product development activities comprising the technology, ALK-positive Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 30+ ALK-positive Non-Small Cell Lung Cancer companies are evaluating 30+ ALK-positive Non-Small Cell Lung Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the ALK-positive Non-Small Cell Lung Cancer market would significantly increase market revenue.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The leading ALK-positive Non-Small Cell Lung Cancer Companies includes GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutica, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Promising ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies includes Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, Phase I: X-396 (ensartinib), Ganetespib, LDK378, Nivolumab, X-396 (ensartinib), and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The ALK-positive Non-Small Cell Lung Cancer companies and academics are working to assess challenges and seek opportunities that could influence ALK-positive Non-Small Cell Lung Cancer R&amp;D. The ALK-positive Non-Small Cell Lung Cancer pipeline therapies under development are focused on novel approaches to treat\/improve ALK-positive Non-Small Cell Lung Cancer.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the ALK-positive Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it&#8217;s a gene rearrangement&mdash;a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Ensartinib: Betta Pharmaceuticals\/Xcovery<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)&ndash;positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1\/2 trial. A single-arm phase 2 trial of ensartinib as second-line treatment for patients with ALK-positive NSCLC previously treated with crizotinib has been completed in 156 Chinese patients, and a New Drug Application has been filed in China. An ensartinib global first-line phase 3 registration trial vs crizotinib is ongoing.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>TQ-B3139 &#8211; Chia Tai Tianqing Pharmaceutical Group<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information, refer to the detailed ALK-positive Non-Small Cell Lung Cancer Unmet Needs, ALK-positive Non-Small Cell Lung Cancer Market Drivers, and ALK-positive Non-Small Cell Lung Cancer Market Barriers, click here for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals\/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ALK-positive Non-Small Cell Lung Cancer Pipeline Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Phases<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mid-stage products (Phase II and Phase I\/II)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<li>Intratumoral<\/li>\n<li>Intravenous<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Gene therapies<\/li>\n<li>Bispecific antibodies<\/li>\n<li>Immunotherapies<\/li>\n<li>Monoclonal antibodies<\/li>\n<li>Small molecules<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>ALK-positive Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutica, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies- Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, Phase I: X-396 (ensartinib), Ganetespib, LDK378, Nivolumab, X-396 (ensartinib), and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>ALK-positive Non-Small Cell Lung Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for drugs for ALK-positive Non-Small Cell Lung Cancer Market Drivers and ALK-positive Non-Small Cell Lung Cancer Market Barriers, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong>&nbsp;<\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Collaboration Deals<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Ensartinib: Betta Pharmaceuticals\/Xcovery<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Bintrafusp alfa: EMD Serono\/GlaxoSmithKline\/Merck<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>PLB1003: Beijing Pearl Biotechnology Limited Liability Company<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Pre-clinical and Discovery Stage Products<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Key Products<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer- Unmet Needs<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Analyst Views<\/li>\n<li>ALK-positive Non-Small Cell Lung Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Got Queries? Find out the related information on ALK-positive Non-Small Cell Lung Cancer Mergers and acquisitions, ALK-positive Non-Small Cell Lung Cancer Licensing Activities @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alk-positive-non-small-cell-lung-cancer-alk-nsclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ALK-positive Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alkpositive-nonsmall-cell-lung-cancer-pipeline-analysis-demonstrates-novel-30-therapies-at-the-horizon-expected-to-transform-the-treatment-paradigm-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alkpositive-nonsmall-cell-lung-cancer-pipeline-analysis-demonstrates-novel-30-therapies-at-the-horizon-expected-to-transform-the-treatment-paradigm-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;ALK-positive Non-Small Cell Lung Cancer Pipeline Insights, 2023,&rdquo; report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alkpositive-nonsmall-cell-lung-cancer-pipeline-analysis-demonstrates-novel-30-therapies-at-the-horizon-expected-to-transform-the-treatment-paradigm-delveinsight_639641.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-639641","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/639641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=639641"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/639641\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=639641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=639641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=639641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}